Evidence map›Paper›PMID 28251187›Full record

ArticleExpert review of precision medicine and drug development2016

A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.

Andrew C Birkeland, Paul L Swiecicki, J Chad Brenner, Andrew G Shuman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert review of precision medicine and drug development, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Andrew C BirkelandHead and Neck Translational Oncology Laboratory, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Otolaryngology-Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, MI.
Paul L SwiecickiHead and Neck Translational Oncology Laboratory, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Otolaryngology-Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, MI; Division of Medical Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI.
J Chad BrennerHead and Neck Translational Oncology Laboratory, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Otolaryngology-Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, MI.
Andrew G ShumanHead and Neck Translational Oncology Laboratory, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Otolaryngology-Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, MI; Center for Bioethics and Social Sciences in Medicine, University of Michigan Medical School, Ann Arbor, MI.
Michigan Center for Translational Pathology · USUniversity of Michigan–Ann Arbor · US

Funding

Dissecting Co-Dependent Pathways in Oral CancersU01DE025184 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BRENNER, JOHN CHADWICK, CAREY, THOMAS E. · 2015 to 2018
$3.7M
Advanced Research Training in OtolaryngologyT32DC005356 · NIDCD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CORFAS, GABRIEL · 2002 to 2021
$3.5M
NIDCD NIH HHS T32 DC005356NIDCR NIH HHS U01 DE025184
6 · The paper itself

Abstract

introductionHead and neck squamous cell carcinoma remains a highly morbid and fatal disease, with poor survival rates among patients with advanced and recurrent disease. Recent advances in next generation sequencing, targeted therapeutics, and precision medicine trials are expanding treatment options for head and neck cancers; thus greater awareness of this rapidly evolving field is important. AREAS COVERED: Recent next-generation sequencing studies in head and neck squamous cell carcinoma, targeted therapy clinical trials involving head and neck squamous cell carcinoma. EXPERT COMMENTARY: This review discusses the current state of head and neck cancer treatment, and considerations and implications for the incorporation of personalized medicine and targeted therapy for head and neck cancers in a dynamic clinical landscape.

Indexed as

head and neck cancerHNSCCpersonalized medicineprecision medicinetargeted therapy

Identifiers

PMID28251187
PMCPMC5328630
OpenAlexW2467846431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.